Press Releases
Launch of the CARE consortia funded by the EU IMI program
18 August 2020
CARE (Corona Accelerated R&D in Europe) a new consortium supported by the Innovative Medicines Initiative (IMI) public-private partnership announced its launch today to accelerate the discovery and development of urgently needed medicines to treat SARS-CoV-2, the virus that causes COVID-19.
Launch of the EHVA consortia funded by the EU H2020 program
27 January 2016
The European HIV Vaccine Alliance (EHVA) is a project funded by EU H2020 program. Its primary objective is to develop a multidisciplinary platform to evaluate novel preventive and therapeutic vaccines. EuroVacc provides the support in the scientific project management.
Start of the EV02 trial in Lausanne and London
16 February 2005
EuroVacc started the phase I trial (EV02) in Lausanne and London to evaluate the safety of DNA-HIV-C alone and of the prime-boost regimen of DNA-HIV-C+NYVAC-HIV-C, and to compare the immunogenicity of the prime-boost regimen to NYVAC-HIV-C alone in healthy volunteers at low risk of acquiring HIV infection.
Results from EV01 trial in Lausanne and London
7 June 2004
The results from the EV01 trial, to evaluate and safety and immunogenicity of NYVAC-C, showed that the vaccine is well tolerated and vaccine-induced T-cell responses were observed in 45% of the vaccine recipients.
Start of the EV01 trial in Lausanne and London
30 July 2003
EuroVacc started the phase I trial (EV02) in Lausanne and London to evaluate the safety of DNA-HIV-C alone and of the prime-boost regimen of DNA-HIV-C+NYVAC-HIV-C, and to compare the immunogenicity of the prime-boost regimen to NYVAC-HIV-C alone in healthy volunteers at low risk of acquiring HIV infection.